Iovance Biotherapeutics Inc (NASDAQ:IOVA) — Market Cap & Net Worth
Market Cap & Net Worth: Iovance Biotherapeutics Inc (IOVA)
Iovance Biotherapeutics Inc (NASDAQ:IOVA) has a market capitalization of $1.03 Billion ($1.03 Billion) as of August 3, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #8632 globally and #2479 in its home market, demonstrating a -20.66% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Iovance Biotherapeutics Inc's stock price $4.07 by its total outstanding shares 396967970 (396.97 Million). Review Iovance Biotherapeutics Inc free cash flow generation to assess how much free cash flow the company generates relative to operating cash flow.
Iovance Biotherapeutics Inc Market Cap History: 2015 to 2026
Iovance Biotherapeutics Inc's market capitalization history from 2015 to 2026. Data shows change from $3.06 Billion to $1.62 Billion (-4.09% CAGR).
Index Memberships
Iovance Biotherapeutics Inc is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.46 Trillion | 0.04% | #251 of 976 |
|
NASDAQ Composite
IXIC
|
$40.26 Trillion | 0.00% | #938 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.72 Trillion | 0.06% | #144 of 263 |
Weight: Iovance Biotherapeutics Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Iovance Biotherapeutics Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Iovance Biotherapeutics Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
17.90x
Iovance Biotherapeutics Inc's market cap is 17.90 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2022 | $2.54 Billion | $238.00K | -$389.92 Million | 10658.09x | N/A |
| 2023 | $3.23 Billion | $1.19 Million | -$444.04 Million | 2714.34x | N/A |
| 2024 | $2.94 Billion | $164.07 Million | -$372.18 Million | 17.90x | N/A |
Competitor Companies of IOVA by Market Capitalization
Companies near Iovance Biotherapeutics Inc in the global market cap rankings as of August 3, 2026.
Key companies related to Iovance Biotherapeutics Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #220 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #424 globally with a market cap of $64.60 Billion USD.
- Argen-X (BR:ARGX): Ranked #543 globally with a market cap of $49.55 Billion USD ( €42.38 Billion EUR).
- UCB SA (BR:UCB): Ranked #563 globally with a market cap of $47.34 Billion USD ( €40.49 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #220 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $477.10 |
| #424 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $64.60 Billion | $762.63 |
| #543 | Argen-X | BR:ARGX | $49.55 Billion | €745.00 |
| #563 | UCB SA | BR:UCB | $47.34 Billion | €222.90 |
Iovance Biotherapeutics Inc Historical Marketcap From 2015 to 2026
Between 2015 and today, Iovance Biotherapeutics Inc's market cap moved from $3.06 Billion to $ 1.62 Billion, with a yearly change of -4.09%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $1.62 Billion | +49.08% |
| 2025 | $1.08 Billion | -63.11% |
| 2024 | $2.94 Billion | -8.98% |
| 2023 | $3.23 Billion | +27.23% |
| 2022 | $2.54 Billion | -66.53% |
| 2021 | $7.58 Billion | -58.86% |
| 2020 | $18.42 Billion | +67.63% |
| 2019 | $10.99 Billion | +212.77% |
| 2018 | $3.51 Billion | +10.62% |
| 2017 | $3.18 Billion | +15.11% |
| 2016 | $2.76 Billion | -9.97% |
| 2015 | $3.06 Billion | -- |
End of Day Market Cap According to Different Sources
On Aug 2nd, 2026 the market cap of Iovance Biotherapeutics Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.03 Billion USD |
| MoneyControl | $1.03 Billion USD |
| MarketWatch | $1.03 Billion USD |
| marketcap.company | $1.03 Billion USD |
| Reuters | $1.03 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Iovance Biotherapeutics Inc
Iovance Biotherapeutics, Inc., a commercial-stage biopharmaceutical company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic me… Read more